ENTRY       D09720                      Drug
NAME        Rilpivirine (JAN/USAN/INN);
            Rekambys (TN)
FORMULA     C22H18N6
EXACT_MASS  366.1593
MOL_WEIGHT  366.4185
CLASS       Antiviral
             DG01889  Non-nucleoside reverse transcriptase inhibitor (NNRTI)
             DG03107  Anti-HIV agent
              DG01656  HIV reverse transcriptase inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
REMARK      Therapeutic category: 6250
            ATC code: J05AG05
            Chemical structure group: DG00663
            Product (DG00663): D09720<JP> D09958<JP/US>
            Product (mixture): D10836<JP/US> D11966<US>
EFFICACY    Antiviral, Reverse transcriptase inhibitor
TARGET      HIV-1 reverse transcriptase [KO:K24802]
  PATHWAY   ko03230(K24802)  Viral genome structure
            ko03240(K24802)  Viral replication
            ko03250(K24802)  Viral life cycle - HIV-1
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
INTERACTION  
STR_MAP     map07053  Anti-HIV agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AG Non-nucleoside reverse transcriptase inhibitors
                 J05AG05 Rilpivirine
                  D09720  Rilpivirine (JAN/USAN/INN) &lt;JP&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D09720  Rilpivirine (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antiviral
              DG01889  Non-nucleoside reverse transcriptase inhibitor (NNRTI)
               DG00663  Rilpivirine
                D09720  Rilpivirine
              DG03107  Anti-HIV agent
               DG01656  HIV reverse transcriptase inhibitor
                DG00663  Rilpivirine
                 D09720  Rilpivirine
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG00663  Rilpivirine
                D09720  Rilpivirine
            Drug classes [BR:br08332]
             Antiviral
              DG03107  Anti-HIV agent
               D09720  Rilpivirine
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HIV reverse transcriptase inhibitor
                D09720  Rilpivirine (JAN/USAN/INN) &lt;JP&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09720
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09720
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09720
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09720
            Drug groups [BR:br08330]
             Antiviral
              DG01889  Non-nucleoside reverse transcriptase inhibitor (NNRTI)
               DG00663  Rilpivirine
              DG03107  Anti-HIV agent
               DG01656  HIV reverse transcriptase inhibitor
                DG00663  Rilpivirine
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG00663  Rilpivirine
            Antimicrobials abbreviations [BR:br08327]
             Antivirals
              Genome replication inhibitor
               HIV reverse transcriptase inhibitor
                DG00663  Rilpivirine
DBLINKS     CAS: 500287-72-9
            PubChem: 124490460
            ChEBI: 68606
            PDB-CCD: T27
            LigandBox: D09720
ATOM        28
            1   C8y C    22.1900  -21.7700
            2   C8x C    22.1900  -23.1700
            3   C8y C    23.4024  -23.8700
            4   C8y C    24.6149  -23.1700
            5   C8y C    24.6149  -21.7700
            6   C8x C    23.4024  -21.0700
            7   N1b N    25.8460  -23.8810
            8   C8y C    27.0512  -23.1853
            9   N5x N    28.2335  -23.8681
            10  C8y C    29.4460  -23.1683
            11  N5x N    29.4462  -21.7683
            12  C8x C    28.2638  -21.0855
            13  C8x C    27.0513  -21.7853
            14  N1b N    30.6770  -23.8793
            15  C8y C    31.8807  -23.1846
            16  C8x C    33.0637  -23.8678
            17  C8x C    34.2762  -23.1681
            18  C8y C    34.2765  -21.7681
            19  C8x C    33.0935  -21.0848
            20  C8x C    31.8810  -21.7846
            21  C1a C    25.8460  -21.0590
            22  C3b C    35.5057  -21.0585
            23  N3a N    36.7181  -20.3585
            24  C2b C    20.9776  -21.0700
            25  C2b C    19.7821  -21.7604
            26  C3b C    18.5947  -21.0749
            27  N3a N    17.3823  -20.3749
            28  C1a C    23.4024  -25.2698
BOND        30
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12   11  12 2
            13   12  13 1
            14    8  13 2
            15   10  14 1
            16   14  15 1
            17   15  16 1
            18   16  17 2
            19   17  18 1
            20   18  19 2
            21   19  20 1
            22   15  20 2
            23    5  21 1
            24   18  22 1
            25   22  23 3
            26    1  24 1
            27   24  25 2
            28   25  26 1
            29   26  27 3
            30    3  28 1
///
